Comments
Loading...

IDEXX Laboratories Analyst Ratings

IDXXNASDAQ
Logo brought to you by Benzinga Data
$415.87
-6.67-1.58%
At close: -
$415.87
0.000.00%
After Hours: Mar 28, 4:00 PM EDT
Consensus Rating1
Overweight
Highest Price Target1
$650.00
Lowest Price Target1
$435.00
Consensus Price Target1
$541.36

IDEXX Laboratories Analyst Ratings and Price Targets | NASDAQ:IDXX | Benzinga

IDEXX Laboratories Inc has a consensus price target of $541.36 based on the ratings of 11 analysts. The high is $650 issued by Goldman Sachs on January 17, 2024. The low is $435 issued by Goldman Sachs on July 21, 2022. The 3 most-recent analyst ratings were released by Piper Sandler, Barclays, and B of A Securities on February 10, 2025, February 4, 2025, and February 4, 2025, respectively. With an average price target of $521.67 between Piper Sandler, Barclays, and B of A Securities, there's an implied 25.44% upside for IDEXX Laboratories Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Oct 24
1
1
Nov 24
1
Dec 24
1
Jan
1
2
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
Barclays
B of A Securities
Morgan Stanley
Leerink Partners

1calculated from analyst ratings

Analyst Ratings for IDEXX Laboratories

Buy NowGet Alert
02/10/2025Buy Now22.63%Piper Sandler
David Westenberg60%
$435 → $510MaintainsNeutralGet Alert
02/04/2025Buy Now25.04%Barclays
Balaji Prasad54%
$481 → $520MaintainsOverweightGet Alert
02/04/2025Buy Now28.65%B of A Securities
Michael Ryskin46%
$475 → $535MaintainsNeutralGet Alert
01/29/2025Buy Now32.25%Morgan Stanley
Erin Wright75%
$559 → $550MaintainsOverweightGet Alert
12/02/2024Buy Now20.23%Leerink Partners
Daniel Clark15%
→ $500Initiates → OutperformGet Alert
11/04/2024Buy Now4.6%Piper Sandler
David Westenberg60%
$520 → $435ReiteratesNeutral → NeutralGet Alert
11/04/2024Buy Now15.66%Barclays
Balaji Prasad54%
$570 → $481MaintainsOverweightGet Alert
10/11/2024Buy Now38.26%JP Morgan
Chris Schott60%
$630 → $575MaintainsOverweightGet Alert
10/10/2024Buy Now20.23%Stifel
Jonathan Block72%
$510 → $500MaintainsHoldGet Alert
08/14/2024Buy Now25.04%Piper Sandler
David Westenberg60%
$600 → $520MaintainsNeutralGet Alert
07/25/2024Buy Now39.47%BTIG
Mark Massaro72%
→ $580Initiates → BuyGet Alert
06/24/2024Buy Now22.63%Stifel
Jonathan Block72%
$520 → $510MaintainsHoldGet Alert
05/14/2024Buy Now43.31%Morgan Stanley
Erin Wright75%
$620 → $596MaintainsOverweightGet Alert
05/02/2024Buy Now37.06%Barclays
Balaji Prasad54%
$655 → $570MaintainsOverweightGet Alert
02/06/2024Buy Now51.49%JP Morgan
Chris Schott60%
$600 → $630MaintainsOverweightGet Alert
02/06/2024Buy Now57.5%Barclays
Balaji Prasad54%
$605 → $655MaintainsOverweightGet Alert
01/30/2024Buy Now26.24%Piper Sandler
David Westenberg60%
→ $525DowngradeOverweight → NeutralGet Alert
01/17/2024Buy Now56.3%Goldman Sachs
Nathan Rich43%
$500 → $650MaintainsBuyGet Alert
11/06/2023Buy Now26.24%Piper Sandler
David Westenberg60%
$520 → $525MaintainsOverweightGet Alert
11/03/2023Buy Now20.23%Goldman Sachs
Nathan Rich43%
$578 → $500MaintainsBuyGet Alert
11/02/2023Buy Now32.25%JP Morgan
Chris Schott60%
$600 → $550MaintainsOverweightGet Alert
11/02/2023Buy Now42.35%Barclays
Balaji Prasad54%
$590 → $592MaintainsOverweightGet Alert
10/30/2023Buy Now10.61%Stifel
Jonathan Block72%
$500 → $460MaintainsHoldGet Alert
09/15/2023Buy Now20.23%Stifel
Jonathan Block72%
$525 → $500MaintainsHoldGet Alert
08/03/2023Buy Now44.28%Morgan Stanley
Erin Wright75%
$590 → $600MaintainsOverweightGet Alert
08/02/2023Buy Now44.28%JP Morgan
Chris Schott60%
$550 → $600MaintainsOverweightGet Alert
08/02/2023Buy Now44.28%Atlantic Equities
Steve Chesney55%
→ $600DowngradeOverweight → NeutralGet Alert
06/07/2023Buy Now44.28%Atlantic Equities
Steve Chesney55%
→ $600ReiteratesOverweight → OverweightGet Alert
05/03/2023Buy Now44.28%Atlantic Equities
Steve Chesney55%
→ $600Reiterates → OverweightGet Alert
03/23/2023Buy Now41.87%Morgan Stanley
Erin Wright75%
$543 → $590MaintainsOverweightGet Alert
02/08/2023Buy Now41.87%Barclays
Balaji Prasad54%
$582 → $590MaintainsOverweightGet Alert
02/07/2023Buy Now32.25%JP Morgan
Chris Schott60%
$525 → $550MaintainsOverweightGet Alert
02/07/2023Buy Now44.28%Atlantic Equities
Steve Chesney55%
$470 → $600MaintainsOverweightGet Alert
01/25/2023Buy Now27.44%Goldman Sachs
Nathan Rich43%
$465 → $530MaintainsBuyGet Alert
11/15/2022Buy Now30.57%Morgan Stanley
Erin Wright75%
$573 → $543MaintainsOverweightGet Alert
11/02/2022Buy Now13.02%Atlantic Equities
Steve Chesney55%
$490 → $470MaintainsOverweightGet Alert
10/17/2022Buy Now8.21%JP Morgan
Chris Schott60%
$525 → $450MaintainsOverweightGet Alert
08/05/2022Buy Now39.95%Barclays
Balaji Prasad54%
$700 → $582MaintainsOverweightGet Alert
08/04/2022Buy Now37.78%Morgan Stanley
Erin Wright75%
$603 → $573MaintainsOverweightGet Alert
08/03/2022Buy Now17.83%Atlantic Equities
Steve Chesney55%
$500 → $490MaintainsOverweightGet Alert
07/26/2022Buy Now0.99%Piper Sandler
David Westenberg60%
$440 → $420MaintainsOverweightGet Alert
07/25/2022Buy Now-0.21%Stifel
Jonathan Block72%
$500 → $415DowngradeBuy → HoldGet Alert
07/21/2022Buy Now4.6%Goldman Sachs
Nathan Rice60%
$530 → $435UpgradeNeutral → BuyGet Alert
07/12/2022Buy Now5.8%Piper Sandler
David Westenberg60%
→ $440Initiates → OverweightGet Alert
06/24/2022Buy Now20.23%Stifel
Jonathan Block72%
$575 → $500MaintainsBuyGet Alert
05/19/2022Buy Now27.44%Goldman Sachs
Nathan Rice60%
$615 → $530MaintainsNeutralGet Alert
05/05/2022Buy Now45%Morgan Stanley
Erin Wright75%
$732 → $603MaintainsOverweightGet Alert
05/05/2022Buy Now13.02%B of A Securities
Michael Ryskin46%
$550 → $470DowngradeBuy → NeutralGet Alert

FAQ

Q

What is the target price for IDEXX Laboratories (IDXX) stock?

A

The latest price target for IDEXX Laboratories (NASDAQ:IDXX) was reported by Piper Sandler on February 10, 2025. The analyst firm set a price target for $510.00 expecting IDXX to rise to within 12 months (a possible 22.63% upside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for IDEXX Laboratories (IDXX)?

A

The latest analyst rating for IDEXX Laboratories (NASDAQ:IDXX) was provided by Piper Sandler, and IDEXX Laboratories maintained their neutral rating.

Q

When was the last upgrade for IDEXX Laboratories (IDXX)?

A

The last upgrade for IDEXX Laboratories Inc happened on July 21, 2022 when Goldman Sachs raised their price target to $435. Goldman Sachs previously had a neutral for IDEXX Laboratories Inc.

Q

When was the last downgrade for IDEXX Laboratories (IDXX)?

A

The last downgrade for IDEXX Laboratories Inc happened on January 30, 2024 when Piper Sandler changed their price target from N/A to $525 for IDEXX Laboratories Inc.

Q

When is the next analyst rating going to be posted or updated for IDEXX Laboratories (IDXX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEXX Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEXX Laboratories was filed on February 10, 2025 so you should expect the next rating to be made available sometime around February 10, 2026.

Q

Is the Analyst Rating IDEXX Laboratories (IDXX) correct?

A

While ratings are subjective and will change, the latest IDEXX Laboratories (IDXX) rating was a maintained with a price target of $435.00 to $510.00. The current price IDEXX Laboratories (IDXX) is trading at is $415.87, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch